Country
Netherlands
Gyroscope Therapeutics Ltd, a gene therapy company founded by Syncona Ltd, has received $148 million in a Series C financing round to advance its lead product for geographic atrophy secondary to age-related macular degeneration (AMD), a leading cause of blindness.
Full text available to subscribers only. Click here for information on subscribing to MedNous.